On October 30, 2026, the U.S. Food and Drug Administration (FDA) approved the first plasmid DNA–based immunotherapy for adults with recurrent respiratory papillomatosis. This approval marks a significant advancement in the treatment options available for this condition.

The new immunotherapy has undergone rigorous evaluation to confirm its safety and efficacy, meeting the FDA's standards for clinical use in the indicated adult population. This regulatory milestone offers a novel therapeutic approach targeting the underlying disease mechanism.

Healthcare professionals treating adults with recurrent respiratory papillomatosis can now consider this plasmid DNA–based immunotherapy as a treatment alternative. Ongoing clinical monitoring will continue to ensure patient safety and treatment effectiveness.